SHAREHOLDER ALERT: CRMD KPLT ANVS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Back to Newsroom
Mentioned in this Article

SHAREHOLDER ALERT: CRMD KPLT ANVS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Tuesday, September 14, 2021 5:40 AM
Share this article now
Topic:
Lawsuits
The Law Offices of Vincent Wong

NEW YORK, NY / ACCESSWIRE / September 14, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

CorMedix Inc. (NASDAQ:CRMD)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/cormedix-inc-loss-submission-form?prid=19558&wire=1
Lead Plaintiff Deadline: September 20, 2021
Class Period: July 8, 2020 - May 13, 2021

Allegations against CRMD include that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Katapult Holdings, Inc. (NASDAQ:KPLT)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/katapult-holdings-inc-loss-submission-form?prid=19558&wire=1
Lead Plaintiff Deadline: October 26, 2021
Class Period: December 18, 2020 - August 10, 2021

Allegations against KPLT include that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Annovis Bio, Inc. (NYSE:ANVS)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=19558&wire=1
Lead Plaintiff Deadline: October 18, 2021
Class Period: May 21, 2021 - July 28, 2021

Allegations against ANVS include that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions